Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of Short Term Lenalidomide on Immune Response to Prevnar 13 in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)

Next Previous
Trial Profile

Impact of Short Term Lenalidomide on Immune Response to Prevnar 13 in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
  • Indications Chronic lymphocytic leukaemia; Lymphocytosis
  • Focus Therapeutic Use

Most Recent Events

  • 15 Jan 2021 Status changed from completed to discontinued.
  • 07 Oct 2019 Status changed from active, no longer recruiting to completed.
  • 04 Oct 2018 Planned primary completion date changed from 1 Jun 2017 to 10 Jul 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top